Talaris Therapeutics Future Growth
Future criteria checks 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Talaris Therapeutics.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Biotechs earnings growth | 21.3% |
| Revenue growth rate | n/a |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 22 Jun 2023 |
Recent future growth updates
Recent updates
Will Talaris Therapeutics (NASDAQ:TALS) Spend Its Cash Wisely?
May 24
Is Talaris Therapeutics (NASDAQ:TALS) In A Good Position To Invest In Growth?
Feb 14We're Keeping An Eye On Talaris Therapeutics' (NASDAQ:TALS) Cash Burn Rate
Oct 21Talaris drops 24% after patient death in late-stage trial for lead asset
Oct 20Talaris Therapeutics: Plenty Of Upside Remains, But So Does The Risk
Aug 29Talaris Therapeutics GAAP EPS of -$0.44
Aug 15We're Not Very Worried About Talaris Therapeutics' (NASDAQ:TALS) Cash Burn Rate
Jul 06Talaris Therapeutics achieves positive results in phase 3 kidney transplant drug trial
Jun 30Talaris Therapeutics (NASDAQ:TALS) Is In A Good Position To Deliver On Growth Plans
Mar 23Talaris Therapeutics EPS beats by $0.49
Jun 14In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Talaris Therapeutics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2023 | N/A | -27 | N/A | N/A | 1 |
| 6/30/2023 | N/A | -75 | -60 | -59 | N/A |
| 3/31/2023 | N/A | -78 | -64 | -61 | N/A |
| 12/31/2022 | N/A | -74 | -64 | -61 | N/A |
| 9/30/2022 | N/A | -70 | -61 | -57 | N/A |
| 6/30/2022 | N/A | -64 | -58 | -54 | N/A |
| 3/31/2022 | N/A | -57 | -51 | -47 | N/A |
| 12/31/2021 | N/A | -48 | -42 | -40 | N/A |
| 9/30/2021 | N/A | -40 | -37 | -36 | N/A |
| 6/30/2021 | N/A | -34 | -32 | -31 | N/A |
| 3/31/2021 | N/A | -27 | -24 | -23 | N/A |
| 12/31/2020 | N/A | -23 | -20 | -19 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if TALS's forecast earnings growth is above the savings rate (2.2%).
Earnings vs Market: Insufficient data to determine if TALS's earnings are forecast to grow faster than the US market
High Growth Earnings: Insufficient data to determine if TALS's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if TALS's revenue is forecast to grow faster than the US market.
High Growth Revenue: Insufficient data to determine if TALS's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if TALS's Return on Equity is forecast to be high in 3 years time